Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12518955 | 0.87 | MAPT (0.54) | KMT2AMEN1TAAR1ALDH1A1MAPT | |
| SCHEMBL385706 | 0.86 | RAB9A (0.59) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| SCHEMBL2340354 | 0.86 | KMT2A (0.71) | KMT2AALDH1A1MAPTRAB9ALMNA | |
| SCHEMBL31442462 | 0.86 | SMN1; SMN2 (0.58) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| SCHEMBL644216 | 0.86 | SMN1; SMN2 (0.58) | KMT2AMEN1ALDH1A1MAPTRAB9A | |
| SCHEMBL31536904 | 0.85 | SMPD1 (0.63) | KMT2AALDH1A1MAPTRAB9AMAPK1 | |
| SCHEMBL6811204 | 0.85 | SMPD1 (0.63) | KMT2AALDH1A1MAPTRAB9AMAPK1 | |
| SCHEMBL15122761 | 0.85 | KMT2A (0.74) | KMT2AMEN1TAAR1ALDH1A1LMNA | |
| SCHEMBL31286940 | 0.85 | RAB9A (0.55) | KMT2AMEN1TAAR1ALDH1A1MAPT | |
| SCHEMBL1989863 | 0.84 | MAPT (0.54) | KMT2AMEN1TAAR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860975-A1 | MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE | Global Blood Therapeutics, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072377-A1 | MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20130022976-A1 | HYPERTHERMOSTABLE ENDONUCLEASE IV SUBSTRATE PROBE | ELITECH HOLDING B.V. | 2013-01-24 | — | — | US | disclosed |
| WO-2011087707-A1 | HYPERTHEROMOSTABLE ENDONUCLEASE IV SUBSTRATE PROBE | ELITECH HOLDING B.V. (NL) | 2011-07-21 | — | — | WO | disclosed |
| US-20110151457-A1 | HYPERTHEROMOSTABLE ENDONUCLEASE IV SUBSTRATE PROBE | ELITECH HOLDING B.V. | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110151457-A1 | HYPERTHEROMOSTABLE ENDONUCLEASE IV SUBSTRATE PROBE | DNASE1, FEN1, UNG | KMT2A 3931/4885MEN1 3421/4885TAAR1 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.